01 March 2014
: Case report 
Interstitial granulomatous dermatitis successfully treated with etanercept
Unknown etiology, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare disease, Adverse events of drug therapy
Zavier Shawkat AhmedBCDEFG, Sabaa JoadACDG, Manpreet SinghAFG, Sabiha S. BandagiADFDOI: 10.12659/AJCR.890074
Am J Case Rep 2014; 15:94-96
Abstract
BACKGROUND: Interstitial granulomatous disease (IGD) is a rare skin condition that presents with erythematous and violaceous plaques, and may be associated with pruritus and pain. The cause remains unknown, but is often associated with autoimmune disease and drug-related adverse effects. It is diagnosed via biopsy, and the treatment remains unclear.
CASE REPORT: We report a case of biopsy-proven IGD associated with rheumatoid arthritis that was treated successfully with etanercept therapy.
CONCLUSIONS: We emphasize that anti-TNF antibodies may be clinically effective for the treatment of IGD.
Keywords: etanercept, rheumatoid arthritis, Interstitial Granulomatous Dermatitis (IGD)
In Press
16 Mar 2024 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.943214
16 Mar 2024 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.943010
16 Mar 2024 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.943687
17 Mar 2024 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.943070
Most Viewed Current Articles
07 Mar 2024 : Case report
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
10 Jan 2022 : Case report 
DOI :10.12659/AJCR.935263
Am J Case Rep 2022; 23:e935263
19 Jul 2022 : Case report 
DOI :10.12659/AJCR.936128
Am J Case Rep 2022; 23:e936128
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250